These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18221603)

  • 1. Current treatments in nonalcoholic steatohepatitis.
    Torres DM; Harrison SA
    Curr Treat Options Gastroenterol; 2007 Dec; 10(6):425-34. PubMed ID: 18221603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions.
    Campbell P; Symonds A; Barritt AS
    Clin Ther; 2021 Mar; 43(3):500-517. PubMed ID: 33583577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis.
    Sayiner M; Lam B; Golabi P; Younossi ZM
    Therap Adv Gastroenterol; 2018; 11():1756284818811508. PubMed ID: 30479664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis.
    Basaranoglu M; Neuschwander-Tetri BA
    Gastroenterol Hepatol (N Y); 2006 Apr; 2(4):282-291. PubMed ID: 28286458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Wong T; Wong RJ; Gish RG
    Gastroenterol Hepatol (N Y); 2019 Feb; 15(2):83-89. PubMed ID: 31011302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Nonalcoholic Fatty Liver Disease.
    Liangpunsakul S; Chalasani N
    Curr Treat Options Gastroenterol; 2003 Dec; 6(6):455-463. PubMed ID: 14585234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology of nonalcoholic steatohepatitis.
    Brunt EM
    Hepatol Res; 2005 Oct; 33(2):68-71. PubMed ID: 16214395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nonalcoholic fatty liver disease].
    Lemoine M; Serfaty L
    Presse Med; 2012 Feb; 41(2):169-89. PubMed ID: 21723084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.
    Westfall E; Jeske R; Bader AR
    Am Fam Physician; 2020 Nov; 102(10):603-612. PubMed ID: 33179890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
    Gottlieb A; Mosthael W; Sowa JP; Canbay A
    Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss.
    Popov VB; Lim JK
    J Clin Transl Hepatol; 2015 Sep; 3(3):230-8. PubMed ID: 26623270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Khan FZ; Perumpail RB; Wong RJ; Ahmed A
    World J Hepatol; 2015 Aug; 7(18):2155-61. PubMed ID: 26328027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
    Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
    Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology.
    Yoon IC; Eun JR
    Yeungnam Univ J Med; 2019 May; 36(2):67-77. PubMed ID: 31620616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.